title: Eosinophilic pustular folliculitis of infancy: a series of 15 cases and review of the literature.
abstract: BACKGROUND
  Eosinophilic pustular folliculitis (EPF) of infancy is characterized by the presence of pustular lesions containing eosinophils. It is the least well-characterized of the EPF diseases.
  
  
  OBJECTIVE
  We sought to define the clinical and histopathologic features of the condition.
  
  
  METHODS
  We conducted a retrospective review of the clinical data and histologic findings of 15 patients given the diagnosis of EPF of infancy at the Hospital Niño Jesús, Madrid, Spain, from 1995 to 2011, and of patient data published in MEDLINE with such a diagnosis from the disease description (1984-2011).
  
  
  RESULTS
  A total of 61 cases were collected. The disease was more common in males than females (ratio 4:1), and presented before 14 months of life in 95% of cases (mean 6.1 months; median 5 months). All patients had recurrent outbreaks and scalp involvement, and 65% had lesions on areas of the body other than the scalp. Tissue eosinophilia was present in all cases; however, true follicular involvement was observed only in 62% of cases in which histologic study was available. More than 80% of the patients were cured by 3 years of age (mean 25.3 months; median 18 months). Topical steroids were effective in 90% of cases.
  
  
  CONCLUSIONS
  This was a retrospective study.
  
  
  CONCLUSIONS
  EPF of infancy presents most often in the first 14 months of life and usually resolves by 3 years of age. All patients showed scalp involvement, tissue eosinophilia, and recurrent outbreaks. The condition does not require aggressive treatment, as it is benign and self-limiting.
authors: Department of Dermatology, Hospital Niño Jesús, Madrid, Spain. ahernandez_hnj@yahoo.es
authors: Ángela
authors: Á
authors: Hernández-Martín
authors: Almudena
authors: A
authors: Nuño-González
authors: Isabel
authors: I
authors: Colmenero
authors: Antonio
authors: A
authors: Torrelo
mesh_terms: D000279:Administration, Cutaneous; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002675:Child, Preschool; D004802:Eosinophilia / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005499:Folliculitis / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D012536:Scalp Dermatoses / Q000188:drug therapy / Q000473:pathology*; D012872:Skin Diseases, Vesiculobullous / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D013030:Spain; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013256:Steroids; D007073:Immunoglobulin E